Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duolingo Inc (DUOL) vs Sana Biotechnology Inc (SANA) Price & Performance

Duolingo IncTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs Sana Biotechnology Inc — how do they compare? Duolingo Inc trades at $133.42 (market cap $5.98B), while Sana Biotechnology Inc trades at $3.51 (market cap $994.89M). The key difference: Duolingo Inc is far larger — about 6× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals.

DUOLSANA
Market Cap
$5.98B$994.89M
Sector
TechnologyHealth
52-Week High
$390.84$5.92
52-Week Low
$90.03$2.68
Enterprise Value
$4.82B$969.08M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duolingo Inc

Duolingo (DUOL) trades at $132.34, up 6.08% in the last session, reflecting strong momentum. The stock shows bullish technical signals with support at $127 and resistance at $135. Fundamentally, revenue grew to $1.04 billion in 2025, with net income surging to $414 million, driven by robust user engagement and AI feature expansion. Recent earnings beats and a positive analyst consensus highlight investor confidence in the company's growth trajectory.

Outlook remains positive with AI-driven user growth and profitability, but risks include rising inference costs and competitive pressures. The stock offers growth potential, yet investors should monitor margin trends and market volatility. Analyst price targets suggest moderate upside from current levels, with a consensus of $108.29.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.

The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA